year 1, Issue 3 (9-2002)                   J. Med. Plants 2002, 1(3): 13-24 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yazdani K, Fotouhi A, Alaedini F, Mirzazadeh A, Arya A, Asghari F, et al . Comparison of therapeutic and short course side effects of Anethum graveolens L. (dill) with other common antihyperlipidemic drugs and placebo in combined hyperlipidemia: A double blind, randomized clinical trial. J. Med. Plants 2002; 1 (3) :13-24
URL: http://jmp.ir/article-1-800-en.html
1- Cardiovascular Research Center, Tehran University of Medical Sciences, Tehran, Iran
2- Cardiovascular Research Center, Tehran University of Medical Sciences, Tehran, Iran , afotouhi@sina.tums.ac.ir
Abstract:   (12836 Views)
The purpose of this clinical trial is a short course study about effectiveness and side effects of Anethum in combined hyperlipidemic patients. Two hundred and ninety eight older than fifteen years old patients with combined hyperlipidemia (serum total cholesterol >240mg/dl and triglyceride >250mg/dl) were included in this controlled, double blind, randomized clinical trial. Two hundred and three patients (68.1%) completed the two months period of trial. After two weeks of therapeutic lifestyle changes (diet and sports), patients were randomized into five following groups 1. Nicotinic Acid 3g daily 2. Nicotinic Acid 3g daily plus Cholestyramine 12g daily 3. Clofibrate 2g daily 4. Anethum 6 tablets daily and 5. Placebo 3 capsules daily. After two months, there was no significant differences between the changes observed in lipid profile in Anethum and placebo groups. Considering the effect on total cholesterol level, the difference between Anethum group (-5%), the first (-22.1%) and the second group (-17.2%) (P<0.000) the effect on triglyceride level, the difference between Anethum group (-16.3%), the first (-54.8%) and the third group (-38%) (P<0.000) and the effect on HDL-cholesterol level, the difference between Anethum group (+1%) and the first group (+30.8%) (P=0.001) was significant. The least complaints were in Anethum group (16%) and the most in the second group (74%). No changes in other biochemical tests were significantly different between Anethum and placebo groups. According to these results there is no superiority for Anethum in comparison of placebo to improve the lipid profile in combined hyperlipidemic patients for a two-month course. Although the side effects of Anethum are less than other well defined drugs.
Full-Text [PDF 273 kb]   (10587 Downloads)    
Type of Study: Research | Subject: Pharmacology & Toxicology
Received: 2001/12/14 | Accepted: 2002/07/7 | Published: 2002/09/3

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb